Compositions and methods for treatment of bleeding disorders
AssigneeBand Therapeutics, LLC
InventorsJames C. Gilbert, Shuhao Zhu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to treatment of bleeding disorders, in particular, hemophilia A (mild, moderate or severe hemophilia) and von Willebrand disease (VWD), Type 1 or Type 2 or Type 3, using VWF targeting agents such as a PEGylated anti-VWF aptamer, BT200.
Claims28
A method for treating bleeding associated with von Willebrand's disease (VWD) in a subject comprising administering to the subject a Von Willebrand factor (VWF) targeting agent which comprises a sequence presented by SEQ ID NO:
- 6, wherein the VWF targeting agent is administered to the subject at a dose ranging from 0.6 mg to 9.0 mg.
A method for treating bleeding in a patient diagnosed with von Willebrand's disease (VWD) with a pharmaceutical composition comprising a VWF binding agent, BT200, comprising:
- a) assessing the baseline coagulation function in said patient;
- b) determining the optimal dose of BT200 with the assessment of step a) for initial treatment;
- and
- c) providing a weekly dose of BT200 after one-week treatment with the initial dose of BT200 in said patient, wherein the initial dose of BT200 is from 0.6 mg to 9.0 mg.
A method of increasing the half-life of a FVIII therapy in a patient who receives the FVIII therapy comprising administering to the patient an VWF targeting agent which comprises a sequence presented by SEQ ID NO:
- 6, and wherein the VWF targeting agent is administered at a dose ranging from 0.6 mg to 9.0 mg.
Dependencies are inferred from the claim text.